Patients with aggressive PCa often undergo ADT treatment, initially effective in extending survival.[79] However, this treatment commonly leads to CRPC, characterized by drug resistance and increased mortality.[35, 79] Our study reveals a novel link between RFX6 expression and resistance to enzalutamide in PCa. This evidence concerns the gene RFX6 and posterior cortical atrophy.